Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Google Disrupts Major Residential Proxy Network IPIDEA 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
SAN DIEGO, May 23, 2017 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Tuesday, June 6, 2017 at 3:30 p.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 30 days.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam®, and Chenodal®.
Contact: Chris Cline, CFA Vice President, Investor Relations & Corporate Communications 646-564-3680 [email protected]
